Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14
|
作者：
Tone, Mari [1 ]
Izumo, Takehiro [1 ]
Awano, Nobuyasu [1 ]
Kuse, Naoyuki [1 ]
Inomata, Minoru [1 ]
Jo, Tatsunori [1 ]
Yoshimura, Hanako [1 ]
Miyamoto, Shingo [2 ]
Kunitoh, Hideo [2 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan
[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan
来源：
LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期
关键词：
immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;
D O I：
10.2217/lmt-2019-0001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [42] Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
    Mittica, Gloria
    Genta, Sofia
    Aglietta, Massimo
    Valabrega, Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (07)
  • [43] Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer
    Pirker, Robert
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 24 - 28
  • [44] Economic analyses of immune-checkpoint inhibitors to treat lung cancer
    Vergnenegre, Alain
    Chouaid, Christos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 365 - 371
  • [45] Role of immune-checkpoint inhibitors in lung cancer
    Jain, Prantesh
    Jain, Chhavi
    Velcheti, Vamsidhar
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [46] Immune Gene Networks from Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Kim, Kyung Soo
    Kang, Taewon
    Jekarl, Dong Wook
    BIOMEDICINES, 2024, 12 (03)
  • [47] Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
    Lefebvre, C.
    Martin, E.
    Hendriks, L. E. L.
    Veillon, R.
    Puisset, F.
    Mezquita, L.
    Ferrara, R.
    Sabatier, M.
    Filleron, T.
    Dingemans, A-M C.
    Besse, B.
    Raherisson, C.
    Mazieres, J.
    RESPIRATORY MEDICINE AND RESEARCH, 2020, 78
  • [48] Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer
    Wu, Jiao
    Zhang, Aifen
    Li, Lu
    Liu, Sicheng
    Yang, Fang
    Yang, Runxiang
    CLINICAL THERAPEUTICS, 2021, 43 (03) : 582 - +
  • [49] Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer
    Wang, Chengdi
    Qiao, Wenliang
    Jiang, Yuting
    Zhu, Min
    Shao, Jun
    Ren, Pengwei
    Liu, Dan
    Li, Weimin
    CANCER MEDICINE, 2019, 8 (08): : 4023 - 4031
  • [50] Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
    Meynard, Lucie
    Dinart, Derek
    Delaunay, Blandine
    Flechon, Aude
    Saldana, Carolina
    Lefort, Felix
    Gravis, Gwenaelle
    Thiery-Vuillemin, Antoine
    Cancel, Mathilde
    Coquan, Elodie
    Ladoire, Sylvain
    Maillet, Denis
    Rolland, Frederic
    Boughalem, Elouen
    Martin, Sophie
    Laramas, Mathieu
    Crouzet, Laurence
    Abbar, Baptiste
    Falkowski, Sabrina
    Pouessel, Damien
    Roubaud, Guilhem
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 43 - 53
12345